These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

74 related articles for article (PubMed ID: 17904701)

  • 1. HIV/AIDS vaccination in adolescents would be efficient and practical when vaccine supplies are limited.
    Johnson LF; Bekker LG; Dorrington RE
    Vaccine; 2007 Oct; 25(43):7502-9. PubMed ID: 17904701
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The potential impact of an HIV vaccine with limited protection on HIV incidence in Thailand: a modeling study.
    Nagelkerke NJ; Hontelez JA; de Vlas SJ
    Vaccine; 2011 Aug; 29(36):6079-85. PubMed ID: 21718745
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The potential impact of a moderately effective HIV vaccine with rapidly waning protection in South Africa and Thailand.
    Andersson KM; Stover J
    Vaccine; 2011 Aug; 29(36):6092-9. PubMed ID: 21703322
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Expected epidemiological impacts of introducing an HIV vaccine in Thailand: a model-based analysis.
    Schneider K; Kerr CC; Hoare A; Wilson DP
    Vaccine; 2011 Aug; 29(36):6086-91. PubMed ID: 21723902
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Murine models for HIV vaccination and challenge.
    Boberg A; Bråve A; Johansson S; Wahren B; Hinkula J; Rollman E
    Expert Rev Vaccines; 2008 Feb; 7(1):117-30. PubMed ID: 18251698
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Human papillomavirus vaccination: what is the best choice? A comparison of 16 strategies by means of a decisional model.
    Gasparini R; Amicizia D; Manfredi P; Ansaldi F; Lucioni C; Gallelli G; Panatto D
    Epidemiol Infect; 2009 Jun; 137(6):794-802. PubMed ID: 18925989
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Preparing for HPV vaccination in South Africa: key challenges and opinions.
    Harries J; Moodley J; Barone MA; Mall S; Sinanovic E
    Vaccine; 2009 Jan; 27(1):38-44. PubMed ID: 18977271
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Predicting the potential impact of a cytotoxic T-lymphocyte HIV vaccine: how often should you vaccinate and how strong should the vaccine be?
    Smith RJ; Schwartz EJ
    Math Biosci; 2008 Apr; 212(2):180-7. PubMed ID: 18359048
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cost-benefit comparisons of investments in improved water supply and cholera vaccination programs.
    Jeuland M; Whittington D
    Vaccine; 2009 May; 27(23):3109-20. PubMed ID: 19428925
    [TBL] [Abstract][Full Text] [Related]  

  • 10. AIDS vaccine: efficacy, safety and ethics.
    Veljkovic V; Veljkovic N; Glisic S; Ho MW
    Vaccine; 2008 Jun; 26(24):3072-7. PubMed ID: 18164521
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The impact of an AIDS vaccine in developing countries: a new model and initial results.
    Stover J; Bollinger L; Hecht R; Williams C; Roca E
    Health Aff (Millwood); 2007; 26(4):1147-58. PubMed ID: 17630459
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Model based analysis of hepatitis B vaccination strategies in the Netherlands.
    Kretzschmar M; Mangen MJ; van de Laar M; de Wit A
    Vaccine; 2009 Feb; 27(8):1254-60. PubMed ID: 19118594
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Modeling the population level effects of an HIV-1 vaccine in an era of highly active antiretroviral therapy.
    Rida W; Sandberg S
    Bull Math Biol; 2009 Apr; 71(3):648-80. PubMed ID: 19214640
    [TBL] [Abstract][Full Text] [Related]  

  • 14. HIV/AIDS and disability in Southern Africa: a review of relevant literature.
    Rohleder P; Braathen SH; Swartz L; Eide AH
    Disabil Rehabil; 2009; 31(1):51-9. PubMed ID: 19194810
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Hepatitis B vaccine: a seven-year study of adherence to the immunization guidelines and efficacy in HIV-1-positive adults.
    Bailey CL; Smith V; Sands M
    Int J Infect Dis; 2008 Nov; 12(6):e77-83. PubMed ID: 18723381
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Dengue fever: from disease to vaccination].
    Teyssou R
    Med Trop (Mars); 2009 Aug; 69(4):333-4. PubMed ID: 19725380
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Broadening inclusion of vulnerable populations in HIV vaccine trials.
    Lau CY; Cardinali M; Sato PA; Fix A; Flores J
    Expert Rev Vaccines; 2008 Mar; 7(2):259-68. PubMed ID: 18324894
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Challenges, lessons learned and results following the implementation of a human papilloma virus school vaccination program in South Australia.
    Watson M; Shaw D; Molchanoff L; McInnes C
    Aust N Z J Public Health; 2009 Aug; 33(4):365-70. PubMed ID: 19689598
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A small dose of HIV? HIV vaccine mental models and risk communication.
    Newman PA; Seiden DS; Roberts KJ; Kakinami L; Duan N
    Health Educ Behav; 2009 Apr; 36(2):321-33. PubMed ID: 18032589
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A review of rotavirus infection in and vaccination of human immunodeficiency virus-infected children.
    Steele AD; Cunliffe N; Tumbo J; Madhi SA; De Vos B; Bouckenooghe A
    J Infect Dis; 2009 Nov; 200 Suppl 1():S57-62. PubMed ID: 19817615
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.